Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

Fig. 5

Co-demonstration of enzastaurin and ibrutinib synergistically inhibit downstream signaling pathways. a Cells were treated with indicated concentration of enzastaurin alone, ibrutinib alone or enzastaurin plus ibrutinib for 60 min and 120 min, and cells harvested for western blot analysis. b The relative phosphorylation levels of signaling mediators were quantified by measuring the relative intensity of phosphorylated bands to the corresponding total bands, results are presented as mean ± SD of three scans. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with control group; # p < 0.05, ## p < 0.01 compared with enzastaurin group

Back to article page